Obesity is associated with an increased risk of various non-communicable diseases such as type 2 diabetes, cardiovascular disease, respiratory problems, and certain cancers. The availability of safe therapeutic compounds for treating obesity is limited, emphasizing the importance of investigating natural remedies as alternatives. Oxyresveratrol, a bioactive compound, has shown promise for the anti-obesity effect. Thus, the present study investigated anti-adipogenesis and lipolysis-inducing activities of oxyresveratrol and oxyresveratrol-enriched extract from Artocarpus lacucha so-called Puag-Haad in culture adipocytes. Treatment of 3T3-L1 adipocytes with these compounds for specific time periods covering differentiation (D0-3), lipogenesis (D3-10), or adipogenesis (D0-10). The intracellular lipid accumulation was determined by Oil Red O-staining and the glycerol release from mature adipocytes was measured and referred to as lipolysis. The result showed that oxyresveratrol and Puag-Haad dose-dependently inhibited lipid accumulation. Suppression during the differentiation period of adipocytes played a critical role in such inhibitory activity. These compounds also effectively induced lipolysis but by different pathways. Puag- Haad-mediated lipolysis depended on β-adrenergic receptors whereas these receptors did not influence the activity of oxyresveratrol. These findings suggest that oxyresveratrol and Puag-Haad hold promise as anti-obesity agents by preventing lipid accumulation in the adipocytes and inducing lipolysis thereby reducing fat mass in adipose tissue.
Key words: Oxyresveratrol, Artocarpus lacucha, Puag-Haad, adipogenesis, lipolysis
|
